Navigation Links
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
Date:12/1/2008

PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCall/ --Genaera Corporation (Nasdaq: GENR) today announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin pathways through the highly selective inhibition of its novel target enzyme, PTP-1B.

Study 102 will establish multiple dose pharmacokinetics (PK) and expand the safety database for MSI-1436 in a population of overweight and obese adult type 2 diabetic subjects who are poorly controlled on metformin. The study will also evaluate key secondary outcomes in this population, including oral glucose tolerance and insulin sensitivity, satiety and weight loss.

"We hope that Study 102 will help establish proof-of-concept for MSI-1436 as a highly competitive treatment for both type 2 diabetes and obesity with a single drug," said Jack Armstrong, President and Chief Executive Officer of Genaera. "In two previous Phase 1 studies, single doses of MSI-1436 administered to over 60 subjects were well-tolerated with an acceptable adverse event profile, exhibited linear PK, produced dose-dependent weight loss and improved insulin sensitivity. We expect the multiple dose data from Study 102 to verify the exciting potential and positive efficacy results of this drug."

Study 102 is a double-blind, randomized, placebo-controlled, safety and PK study being conducted at two U.S. sites. The study will initially enroll 21 subjects at three dose levels (3, 6, and 10 mg/m2) of MSI-1436 with treatment occurring every three days over a 23 day period. Five subjects in each dosing group will receive
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... LOS ANGELES , Aug. 29, 2014 /PRNewswire/ ... providing both financing alternatives and turnkey support services ... to announce that FINRA processed and approved the ... August 29, 2014, CannaMed Corporation will be known ... name change was accomplished through a merger with ...
(Date:8/29/2014)... NEW YORK , Aug. 29, 2014 ... EDAP TMS S.A. ("EDAP" or the "Company") (NASDAQ: ... action, filed in United States District Court, Southern District ... under 14-cv-6069, is on behalf of a class consisting ... between February 1, 2013 and July 30, 2014, inclusive ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Sept. 29, 2011 CVS/pharmacy,s ExtraCare Rewards ... 69 million active cardholders, today announced the continuation of ... fun and useful digital resources on CVS.com and the ... ExtraBucks® Rewards, just in time for the October 1 ...
... Calif. and SAN DIEGO, Sept. 29, 2011 Verinata ... fetal health, today announced it has signed a three-year ... manufacturer of life sciences tools for the large-scale analysis ... terms of the agreement, Verinata Health will purchase Illumina,s ...
Cached Medicine Technology:CVS/pharmacy Continues Digital "MoneyTrashers" Campaign, Enlists Shoppers to Pledge to "Stop Money Trashing" 2CVS/pharmacy Continues Digital "MoneyTrashers" Campaign, Enlists Shoppers to Pledge to "Stop Money Trashing" 3Verinata Health Announces a Multi-Year Supply Agreement with Illumina in the Field of Non-Invasive Prenatal Diagnostics 2
(Date:8/30/2014)... Flagstaff, AZ (PRWEB) August 30, 2014 Jake ... High School while in the Back2Basics Outdoor Adventures ... want to finish high school so I can actually start ... need English and math, and I'm done.” , He has ... the initial Back2Basics program. Most clients choose to continue on ...
(Date:8/30/2014)... Ohio (PRWEB) August 30, 2014 As 500 ... birth defect when give to pregnant mothers, Wright & Schulte ... Judge Cynthia M. Rufe. The remand in the ... representative of 18 states and are involved in one ... them to have their Zoloft birth defect lawsuit sent back ...
(Date:8/30/2014)... GA (PRWEB) August 30, 2014 The ... Open Challenge and K.Warrior Search on November 8th, 2014 ... 20 years, these events have introduced many notorious and ... as Strike-Force, IWF and the UFC. , Among ... numerous fighters leave its doors armed with the virtues ...
(Date:8/30/2014)... Saturday 30 August 2014: The first comprehensive ESC Guidelines ... at ESC Congress 2014 by Task Force Chairpersons Professor ... The "2014 ESC Guidelines on the diagnosis and treatment ... European Heart Journal (1) and on the ... were published in 2001 but they were restricted to ...
(Date:8/29/2014)... The Enchant Him review that was recently ... is a system that promises to teach ladies how to ... Carrie Engel, who actually is a popular relationship expert and ... the best advices out there, Carrie worked at this program ... new program is a simple to use step by step ...
Breaking Medicine News(10 mins):Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First comprehensive ESC Guidelines on aortic diseases published 2Health News:First comprehensive ESC Guidelines on aortic diseases published 3Health News:Enchant Him Review Reveals Unique Relationship Tips for Women 2
... together explained that they have identified the gene that ... caused by an abnormal build up of iron in ... the PLA2G6 gene, whose mutated forms trigger several genetic ... could also shed light on the nerve cell degeneration ...
... Institute finds children who have habit of eating foods high ... ,Therefore, TSI warned parents to be cautious about ... the market, which was concluded after surveying about 270 processed ... was evident that children’s consuming food with highest fat content ...
... antidepressants to the REM Sleep Behavior Disorder (RBD). The ... causes //the onset of this disorder at a younger ... where patients act out their dreams, which are often ... medicine specialist, neurologist and study investigator. This acting out ...
The Indian Institute of Management, Ahmedabad (IIMA) here Monday signed a memorandum of understanding (MoU) with the US-based Duke Corporate Education //CE to offer customised corporate education prog...
... More than 25 children have died of suspected encephalitis and ... Muzaffarpur district for the past few days //. ... the spread of the killer disease. The children reported sudden ... bouts of unconsciousness and convulsion leading to their death. ...
... childbirth to ease the pain during labor. But such epidurals ... National Patient Safety Agency (NPSA) in response has issued warnings ... that about 200 errors have been committed due a period ... be administered at the base of the spine, but in ...
Cached Medicine News:Health News:Rare Nerve Disease Causing Gene Identified 2
Transcranial vascular DWL doppler....
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
Medicine Products: